Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §102 only | 2 (40%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.9% | +46.1% |
| SHIM, DAVID M. | 1 | 58.8% | +56.0% |
| MCKOY, QUINCY ANDRE | 1 | 68.5% | +41.7% |
| VAJDA, KRISTIN ANN | 1 | 84.1% | +10.6% |
| SHOWALTER, ALEXANDER KEITH | 1 | 52.1% | +53.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009206 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | VAJDA, KRISTIN ANN | 9d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009194 | 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | SHOWALTER, ALEXANDER KEITH | 77d overdue |
| 18501729 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | HUTTER, GILLIAN A | 8d overdue |
| 18009206 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | VAJDA, KRISTIN ANN | 9d |
| 18009172 | HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | SHIM, DAVID M. | 23d |
| 18043298 | PHARMACEUTICAL COMBINATION AND TUMOR TREATMENT | MCKOY, QUINCY ANDRE | 75d |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1625 | 1 |
| 1622 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18501729 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | HUTTER, GILLIAN A | 1625 | Other | Non-Final OA | 8d overdue | Pending | Nov 03, 2023 |
| 18009172 | HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | SHIM, DAVID M. | 1626 | §103 | Non-Final OA | 23d | Pending | Jul 17, 2023 |
| 18043298 | PHARMACEUTICAL COMBINATION AND TUMOR TREATMENT | MCKOY, QUINCY ANDRE | 1626 | §103 | Final Rejection | 75d | Pending | May 23, 2023 |
| 18009206 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | VAJDA, KRISTIN ANN | 1622 | §102 | Final Rejection | 9d | Pending | Dec 08, 2022 |
| 18009194 | 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | SHOWALTER, ALEXANDER KEITH | 1629 | §102 | Final Rejection | 77d overdue | Pending | Dec 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial